No difference in insulin resistance and lipid levels between controls and adolescent subjects who later develop psychosis

Schizophrenia Research

Volumn 104, Issue 1-3, 2008, Pages 31-35

  Koponen, H ^a,b   Vuononvirta, J ^c   Maki P ^c,d   Miettunen, J ^b,c   Moilanen, I ^d   Taanila, A ^c,d   Ruokonen, A ^c   Veijola, J ^b,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b ACADEMY OF FINLAND   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cholesterol; Follow up; Glucose; Insulin resistance; Psychosis; Triglycerides

Indexed keywords

GLUCOSE; INSULIN; LIPID;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DEPRESSIVE PSYCHOSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART MUSCLE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHOOL CHILD; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CATCHMENT AREA (HEALTH); FINLAND; HEALTH BEHAVIOR; HOSPITALIZATION; HUMANS; INSULIN RESISTANCE; LIFE STYLE; LIPOPROTEINS; PSYCHOTIC DISORDERS; REGISTRIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 50349083950     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.05.021     Document Type: Article

References (28)

1. a-receptors predict clinical response to olanzapine in first-episode schizophrenia patients. Psychiatry Res. 153 (2007) 103-109
2. Attux C., Quintana M.I., and Chaves A.C. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Review Brasilia Psyquiatria 29 (2007) 346-349
3. Brandou F., Brun J.-F., and Mercier J. Limited accuracy of surrogates of insulin resistance during puberty in obese and lean children at risk for altered glucoregulation. J. Clin. Endocrinol. Metab. 90 (2005) 761-767
4. Cohn T.A., Remington G., Zipursky R.B., Azad A., Connolly P., and Wolever T.M. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can. J. Psychiatry 51 (2006) 382-386
5. Correll C.U., Frederickson A.M., Kane J.M., and Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J. Clin. Psychiatry 67 (2006) 575-583
6. De Hert M., Schreurs V., Sweers K., Van Eyck D., Hanssens L., Sinko S., Wampers M., Scheen A., Peuskens J., and van Winkel R. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 101 1-3 (2008) 295-303 10.1016/j.schres.2008.01.028
7. De Leon J., Correa J.C., Ruano G., Windemuth A., Arranz M.J., and Diaz F.J. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr. Res. 98 (2008) 40-46
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summery of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
9. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92 (2007) 399-404
10. Heilä H., Haukka J., Suvisaari J., and Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol. Med. 35 (2005) 725-732
11. Juvonen H., Reunanen A., Haukka J., Muhonen M., Suvisaari J., Arajärvi R., Partonen T., and Lönnqvist J. Incidence of schizophrenia in nationwide cohort of patients with type 1 diabetes mellitus. Arch. Gen. Psychiatry 64 (2007) 894-899
12. Järvelin M.R., Elliott P., Kleinschmidt I., Martuzzi M., Grundy C., Hartikainen A.L., and Rantakallio P. Ecological and individual predictors of birthweight in a northern Finland birth cohort 1986. Paediatr. Perinat. Epidemiol. 11 3 (1997) 298-312
13. Isohanni M., Mäkikyrö T., Moring J., Räsänen P., Hakko H., Partanen U., Koiranen M., and Jones P. A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Clinical and research diagnoses of schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 32 (1997) 303-308
14. Katz A., Nambi S.S., Mather K., Baron A.D., Follman D.A., Sullivan G., and Quon M.J. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85 (2000) 2402-2410
15. Koponen H., Mäki P., Halonen H., Miettunen J., Laitinen J., Tammelin T., Moilanen I., Taanila A., Ruokonen A., Korkeila J., and Veijola J. Insulin resistence and lipid levels in adolescents with familial risk for psychosis. Acta Psychiatr. Scand. 117 (2008) 337-341
16. Mathews D.R., Hosker J.P., Rudenski A.A., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
17. Newcomer J.W. Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry 67 11 (2006) e16
18. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
19. Perez-Iglesias R., Crespo-Farocco B., Martinez-Garcia O., Ramirez-Bonnilla M.L., Alvarez-Jiminez M., Pelayo-Teran J.M., Garcia-Unzuenta M.T., Amado J.A., and Vazquez-Barbuero J.L. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr. Res. 99 (2008) 13-22
20. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
21. Saari K., Lindeman S., Koponen H., Jokelainen J., and Isohanni M. Higher serum triglyceride levels in early-onset schizophrenia. Am. J. Psychiatry 161 (2004) 176
22. Saddichha S., Manjunatha N., Ameen S., and Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J. Clin. Psychiatry 68 (2007) 1793-1798
23. Saha S., Chant D., and McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 64 (2007) 1123-1131
24. Spelman L.M., Walsh P.I., Sharifi N., Collins P., and Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 24 (2007) 481-485
25. Straus M.J.M., Bleumink G.S., Dieleman J.P., van der Lei Jong G.W., Kingma J.H., Sturkenboom M.C.J.M., and Stricker B.H.C. Antipsychotics and the risk of sudden cardiac death. Arch. Intern. Med. 164 (2004) 1293-1297
26. Tenerz A., Norhammar A., Silveira A., Hamsten A., Nilsson G., Ryden L., and Malmberg K. Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 26 (2003) 2770-2776
27. Thakore J.H. Metabolic syndrome and schizophrenia. Br. J. Psychiatry 186 (2005) 455-456
28. Tuulio-Henriksson A., Partonen T., Suvisaari J., Haukka J., and Lönnqvist J. Age at onset and cognitive functioning in schizophrenia. Br. J. Psychiatry 185 (2004) 215-219